Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Automatic implantable cardioverter defibrillator. Current status.

A S Manolis1, H Rastegar, N A Estes

  • 1Cardiac Arrhythmia Service, Tufts University School of Medicine, New England Medical Center, Boston, Mass. 02111.

JAMA
|September 8, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.

Journal of the American Heart Association·2026
Same author

Mortality, Hospitalization, and Cardiac Interventions Among Patients With Mitral Valve Prolapse <65 Years of Age.

Journal of the American Heart Association·2026
Same author

Mortality, Hospitalization, and Cardiac Interventions in Patients With Atrial Fibrillation Aged <65 Years.

Circulation. Arrhythmia and electrophysiology·2024
Same author

Recent Developments in Cardiac Pacemakers: Rate-Responsive Pacing.

The Physician and sportsmedicine·2016
Same author

Monitoring dithiocarbamate fungicide residues in greenhouse and non-greenhouse tomatoes in Iran by HPLC-UV.

Food additives & contaminants. Part B, Surveillance·2014
Same author

Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2011
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
See all related articles

The automatic implantable cardioverter defibrillator (AICD) detects and stops life-threatening heart rhythms like ventricular fibrillation. Since 1980, AICD technology has advanced, significantly reducing sudden cardiac death in high-risk patients.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • The automatic implantable cardioverter defibrillator (AICD) was developed to treat ventricular fibrillation.
  • Over 5000 AICDs have been implanted since the first human implant in 1980.
  • Clinical experience with AICDs has grown substantially.

Purpose of the Study:

  • To review the evolution and impact of AICD technology.
  • To assess the effectiveness of AICDs in managing cardiac arrhythmias.
  • To evaluate the reduction in arrhythmic mortality and sudden death rates.

Main Methods:

  • Review of clinical data and technological advancements in AICDs.
  • Analysis of implant numbers and patient outcomes.
  • Assessment of the device's capability in sensing and terminating ventricular tachycardia and fibrillation.

Related Experiment Videos

Main Results:

  • AICD technology has rapidly evolved since its inception.
  • The device can now detect and terminate both ventricular tachycardia and fibrillation.
  • A significant reduction in sudden death rates has been observed in patients with AICDs.

Conclusions:

  • The AICD has made a major impact on reducing arrhythmic mortality.
  • Despite not being an ideal antiarrhythmic device, it effectively lowers sudden death rates.
  • AICDs are a crucial intervention for high-risk patient populations experiencing life-threatening arrhythmias.